ArticleBMC gastroenterology2026
Interpretable machine learning model for predicting 5-Year postoperative recurrence risk in patients with stage III colon cancer using preoperative laboratory tests: a two-centre study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is one of the most prevalent malignant diseases worldwide and displays significant heterogeneity. The aim of this study was to investigate the application of machine learning algorithms to incorporate preoperative laboratory tests for predicting the 5-year recurrence risk in patients with stage III colon cancer (CC) postsurgery.
methodsThis study included two patient cohorts: the Zhejiang Cancer Hospital CC cohort (ZCC set, n = 290), which served as the training cohort, and the Dongyang CC cohort (DYC set, n = 125), which was utilized as an external testing cohort. Univariate analysis was initially performed on the 48 preoperative laboratory tests and 15 clinical and pathological features within the training cohort to pinpoint potential predictors. Features with a p value less than 0.05 were incorporated, and six machine learning models-logistic regression, random forest, XGBoost, support vector machine (SVM), back propagation neural network (BP NET), and K-nearest neighbour (KNN)-were employed to develop a model for predicting the 5-year recurrence risk in patients with stage III colon cancer. The prediction efficacy was assessed by calculating the area under the curve (AUC) of the machine learning model using the external test dataset, and comparisons were performed via the DeLong test. Ultimately, the Shapley additive explanations (SHAP) algorithm was applied to rank feature importance and compute the SHAP values for each feature, which were then visualized.
resultsUnivariate analysis identified 10 laboratory tests and 6 clinical and pathological features that were incorporated into six machine learning models. The random forest model exhibited the highest predictive performance in the test cohort, with an AUC of 0.845. Logistic regression closely trailed, achieving an AUC of 0.823. The DeLong test revealed that the predictive performance of the random forest model was comparable to that of logistic regression and outperformed the other models. SHAP analysis indicated that the most important feature for predicting the 5-year recurrence risk of stage III colon cancer was perineural invasion, followed by FIB and then PT.
conclusionsA machine learning model constructed using preoperative laboratory tests and clinical and pathological features can assist in predicting the 5-year recurrence risk of patients with stage III colon cancer. This model provides potential reference values for the clinical development of individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.